ArrowMark Colorado Holdings LLC Trims Position in Perrigo Company plc $PRGO

ArrowMark Colorado Holdings LLC lessened its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 41.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 307,000 shares of the company’s stock after selling 221,000 shares during the period. ArrowMark Colorado Holdings LLC owned approximately 0.22% of Perrigo worth $6,837,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Bahl & Gaynor Inc. raised its position in Perrigo by 5.4% during the third quarter. Bahl & Gaynor Inc. now owns 2,087,075 shares of the company’s stock worth $46,479,000 after acquiring an additional 107,774 shares during the period. Cooke & Bieler LP boosted its holdings in shares of Perrigo by 11.6% during the 3rd quarter. Cooke & Bieler LP now owns 3,680,411 shares of the company’s stock worth $81,963,000 after purchasing an additional 381,290 shares during the last quarter. Diamond Hill Capital Management Inc. boosted its stake in Perrigo by 8.6% during the third quarter. Diamond Hill Capital Management Inc. now owns 1,797,746 shares of the company’s stock worth $40,036,000 after buying an additional 142,363 shares during the last quarter. Nicola Wealth Management LTD. grew its holdings in shares of Perrigo by 38.4% in the third quarter. Nicola Wealth Management LTD. now owns 281,000 shares of the company’s stock valued at $6,257,000 after purchasing an additional 78,000 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Perrigo by 2.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock worth $171,367,000 after buying an additional 181,828 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Performance

Shares of PRGO stock opened at $9.30 on Monday. The company has a current ratio of 2.76, a quick ratio of 1.63 and a debt-to-equity ratio of 1.23. The stock has a 50 day simple moving average of $13.77 and a 200-day simple moving average of $16.50. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -0.90, a price-to-earnings-growth ratio of 1.12 and a beta of 0.41. Perrigo Company plc has a 12-month low of $9.23 and a 12-month high of $29.08.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the prior year, the company earned $0.93 EPS. The company’s revenue was down 2.5% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 24th. Investors of record on Monday, March 2nd will be issued a $0.29 dividend. The ex-dividend date is Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 12.5%. Perrigo’s dividend payout ratio is currently -11.28%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Canaccord Genuity Group cut their price objective on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a research note on Friday, February 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Argus raised shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Perrigo has a consensus rating of “Hold” and an average target price of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.